Pathology International · 2012 · 61 citations · 17 references
MedicineOncologyPathologyCancer ImmunologyMolecular OncologyMonoclonal AntibodiesAntibody CharacterizationHla TypingHuman Leukocyte Antigen SystemImmunohistochemistryTumor AntigensTumor-associated AntigensClass I Hla AntibodiesHla Antigen ExpressionHla Class I MoleculesHla Expression LevelsHla LossImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical Staining
A novel monoclonal anti-pan human leukocyte antigen (HLA) class I heavy chain antibody, EMR8-5, was established. It could detect HLA-A, -B, and -C antigens in formalin-fixed paraffin embedded tissues. By immunohistochemical staining using the EMR8-5 antibody, various cancer tissues from 246 cases were examined for HLA class I expression. It was found that HLA class I expression was decreased in 20% to 42% of the cases of lung cancer, hepatocellular carcinoma, colon cancer, renal cell carcinoma, and urothelial carcinoma. In contrast, 85% of breast cancer cases had loss of or decreased HLA class I expression. Of the 35 breast cancer cases that had decreased HLA class I heavy chain expression, 33 (94%) also had decreased beta2-microglobulin expression detected by immunohistochemical staining. It was suggested that HLA class I down-regulation might be a common characteristic of breast cancer mostly caused by the down-regulation of beta2-microglobulin expression.
17
Nico J. Stam, Th. M. Vroom, Paul J. Peters et al. · International Immunology · 1990 · 250 citations
Life Sciences, Immunology, Pathology +16
Tetsuhiro Tsuruma, Fumitake Hata, Toshihiko Torigoe et al. · Journal of Translational Medicine · 2004 · 181 citations · Full text
Medicine, Immunology, Oncology +17
Andrés López‐Albaitero, Jayakar V. Nayak, Takeshi Ogino et al. · The Journal of Immunology · 2006 · 157 citations · Full text
Life Sciences, Immunology, Oncology +17